On 26 February, Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, today announced that it has signed four commercial license agreements (CLAs) with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The CLAs extend the companies’ previous agreement through which Selexis is providing Xencor with access to its SUREtechnology Platform™, as well as cell line development-related services that include personnel, laboratory equipment and laboratory space.

Complete press release
Find an actor

MEDICA 201812.11.2018

MEDICA 2018 will be back in Düsseldorf from 12 to 15 November.

"Hidden estrogen receptors in the breast epithelium"

"EPFL scientists have uncovered that next to estrogen receptor-positive and -negative cells, there are cells with very...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn